RPL5

Across TCGA pan-cancer cohorts, RPL5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPL5 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL5 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

CCRCC, GBM, and COAD are the cancer types where RPL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.504	0.822	.009	17	view →
GBM	DFS	Median	All	0.267	0.478	.002	13	view →
COAD	DFS	Median	III,IV	1.000	0.890	.029	12	view →
LUAD	DFS	Median	III,IV	0.805	0.247	.001	12	view →
PDAC	OS	Tertile	IV	0.425	0.962	.024	8	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.617	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL5–CCRCC (OS)

Open the CCRCC breakdown →